Pimavanserin Moves Toward First-Line Use for Parkinson's Psychosis
Compiled by Carlat Editorial Staff and Reviewed by the Editor-in-Chief and the Editorial Board.
Staff members have no financial relationships with companies related to this material.
Compiled by Carlat Editorial Staff and Reviewed by the Editor-in-Chief and the Editorial Board.
Staff members have no financial relationships with companies related to this material.
Brian Holoyda, MD, MPH, MBA. Chief Psychiatrist, Contra Costa County Detention Health Services, Martinez, CA.
Dr. Holoyda has no financial relationships with companies related to this material.
Reviewed by Jesse Koskey, MD. Dr. Koskey has no financial relationships with companies related to this material.
Christine Tran-Boynes, DO.
Dr. Tran-Boynes has no financial relationships with companies related to this material.
Richard Moldawsky, MD. Dr. Moldawsky has no financial relationships with companies related to this material.
Jonathan G. Leung, PharmD, RPh, Clinical pharmacist specialist, Mayo Clinic, Rochester, MN. Associate Professor of Pharmacy and Associate Professor of Psychiatry, Mayo Clinic, College of Medicine and Science.
Dr. Leung has no financial relationships with companies related to this material.
Simon M. Dosovitz, MD.
Dr. Dosovitz has no financial relationships with companies related to this material.
Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.
© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.